Health Care·Biotechnology·$6.7B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.11 | N/A | +36.42% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-0.11 | N/A | +36.42% |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Management expressed concerns about market conditions but remains committed to its long-term strategy. They did not provide any updates on guidance.
Management did not provide specific guidance for future quarters.
The company is focused on strategic initiatives despite current challenges.
Erasca's earnings report shows a narrower-than-expected loss per share, which is a positive surprise. However, the lack of revenue data and guidance may have contributed to the stock's decline of 3.86%. Investors are likely concerned about the company's future performance without clear direction from management.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
ICL GROUP LTD
Nov 11, 2024